Group 1 - The China Securities Regulatory Commission (CSRC) disclosed that four companies have recently received domestic listing guidance approval from August 11 to August 17 [1] - The companies include InnoCare Medical Technology (Suzhou) Co., Zhejiang Ouno Machinery Technology Co., China Aerospace Technology Co., and Jiangsu Handian Biotechnology Co. [1] - China Aerospace Technology Co. is projected to incur a net loss of 748 million yuan in 2024 but is still eligible for an IPO due to the inclusion of commercial aerospace in the "not yet profitable" green channel for the Sci-Tech Innovation Board [1] Group 2 - In the past month, three commercial aerospace companies have initiated their IPO processes [1] - Handian Biotechnology's stock was previously listed on the National Equities Exchange and Quotations system on January 6, 2017 [1]
本周新增中科宇航、汉典生物等4家企业完成境内IPO辅导备案
Sou Hu Cai Jing·2025-08-17 03:09